{
  "docId": "019de072-1de2-7119-a555-9ff409e7e548",
  "docSlug": "506aa41f1d83c0fffcc1a747d59c4e2b",
  "documentTitle": "Bausch Health Companies | Results Presentation Deck | 86 slides",
  "authorId": "bausch-health-companies",
  "authorName": "Bausch Health",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-02-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.3333334,
  "pageNumber": 6,
  "pageCount": 86,
  "prevPage": 5,
  "nextPage": 7,
  "slideType": "roadmap",
  "function": "plan_implementation",
  "density": "dense",
  "nDataPoints": 1,
  "notes": "The slide uses a checklist format to distinguish between completed actions (checked) and future actions (unchecked).",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de072-1de2-7119-a555-9ff409e7e548/6",
  "deckHref": "/decks/019de072-1de2-7119-a555-9ff409e7e548",
  "deckJsonHref": "/decks/019de072-1de2-7119-a555-9ff409e7e548.json",
  "deckAnchorHref": "/decks/019de072-1de2-7119-a555-9ff409e7e548#slide-6",
  "components": [
    {
      "bbox": {
        "h": 0.1,
        "w": 0.35,
        "x": 0.6,
        "y": 0.82
      },
      "kind": "callout",
      "text": "This presentation does not constitute an offer to sell or the solicitation of an offer to buy any securities.",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "75db6373-6fcb-4b75-bf3f-ea0f0f2e909b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.7,
        "w": 0.9,
        "x": 0.05,
        "y": 0.15
      },
      "kind": "list",
      "text": "Complete financial segmentation of Bausch + Lomb and Solta Medical\nAppoint leadership of Bausch Pharma, Bausch + Lomb and Solta Medical\nSignificant debt paydown of ~$1.84B since announcement of strategic alternatives process\nSubstantially complete in our preparations and planning for the Bausch + Lomb IPO\nSubstantially complete in our preparations and planning for the Solta Medical IPO\nRaised new debt to refinance certain existing debt and announced refinancing of existing BHC credit facilities to facilitate B+L IPO and full separation\nAnnounced public filing of S-1s relating to the proposed IPOs of Bausch + Lomb and Solta Medical\nLaunch Bausch + Lomb IPO subject to market conditions\nLaunch Solta Medical IPO subject to market conditions\nBausch + Lomb spinoff following the expiry of customary lock-ups related to the B+L IPO, achievement of our target net leverage ratios and subject to market conditions",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3fe6139f-7d94-499a-b7c8-27e62a94e0b2",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.7,
        "x": 0.25,
        "y": 0.93
      },
      "kind": "source-note",
      "text": "1. See Slide 1 for further information on forward-looking statements. 2. The remainder of Bausch Health is referred to as \"Bausch Pharma\" and will assume a new name upon the separation of the Company's eye health business, Bausch + Lomb. 3. Net of $285M revolver draw down as of 12/31/2021. 4. Subject to market conditions, other factors and regulatory, stock exchange and other approvals. 5. Subject to receipt of applicable shareholder and other necessary approvals and factors. 6. There can be no assurance that the refinancing of our existing credit facilities will be consummated on the on anticipated terms, or at all.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "61aaa8ae-f2d3-490d-be7c-b9c7d9a2d958",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.9,
        "x": 0.05,
        "y": 0.04
      },
      "kind": "title",
      "text": "Accelerating Strategic Alternatives to Drive Shareholder Value",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "681d4bdf-b3b1-49a2-83fa-265dc21da7ed",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "roadmap",
      "slug": null,
      "matchId": "fb50d386-5b34-47a0-ab17-279f50840638",
      "evidence": "The slide outlines a sequence of strategic milestones to be achieved over time.",
      "confidence": 0.9
    }
  ],
  "arcBeats": [],
  "loops": [
    {
      "to": 9,
      "from": 5,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "124322e1-2f78-4306-910b-25b30d964ee2",
      "evidence": "The presentation highlights the need for strategic alternatives, implying that inaction will have negative consequences",
      "position": 0,
      "objective": "What are the consequences of not taking action?",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.6,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}